作者：
Park, E. [1]
;
Gintant, G. [2]
;
Bi, D. [3]
;
Kozeli, D. [4]
;
Pettit, S. [5]
;
Pierson, J. [6]
;
Skinner, M. ;
Willard, J. ;
Wisialowski, T. ;
Koerner, J. ;
Valentin, J.
作者单位：
AstraZeneca, Drug Safety & Metab, Macclesfield, Cheshire, England
[1]
UCB Biopharma SPRL, Nonclin Dev, Braine Lalleud, Belgium
[2]
US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[3]
Pfizer, Drug Safety Res & Dev, Groton, CT USA
[4]
HESI, Washington, DC USA
[5]
AbbVie, Integrat Pharmacol, N Chicago, IL USA
[6]
发布时间
2017-11-12
换一批
